All In Biotech

Drug Trial Radar · NCT06730100

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Sep 11, 2025

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Sponsor type
NIH
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well CBX-12 works in treating patients with microsatellite stable colorectal cancer that has spread to other parts of the body (metastatic) and is no longer responding to chemotherapy treatment (chemotherapy-refractory). The usual approach to treating colorectal cancer includes treatment with surgery, radiation, or Food and Drug Administration (FDA)-approved drugs such as trifluridine-tipiracil, bevacizumab, regorafenib, or fruquintinib. However, most metastatic colorectal patients progress through all approved treatments and eventually succumb to their disease. CBX-12 is a drug that contains a peptide (a substance that contains many amino acids \[molecules that join together to form proteins\]) called pHLIP, linked to an anticancer substance called exatecan. Upon administration, pHLIP gets inserted into the cellular membrane of tumor cells, delivering exatecan to kill them. Giving CBX-12 may work better than the usual approach in treating patients with metastatic chemotherapy-refractory microsatellite stable colorectal cancer.

Conditions

  • Metastatic Mismatch Repair Proficient Colorectal Carcinoma
  • Refractory Mismatch Repair Proficient Colorectal Carcinoma
  • Stage IV Colorectal Cancer AJCC v8

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT scan

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • pH Low Insertion Peptide-exatecan Conjugate CBX-12Drug

    Given IV

  • X-Ray ImagingProcedure

    Undergo chest x-rays

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: From registration to disease progression or death due to any cause, assessed up to 12 months
  2. Dose limiting toxicities (DLTs)Time frame: Baseline up to 12 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Northwestern University

    Chicago, Illinois

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York

  • University of Cincinnati Cancer Center-UC Medical Center

    Cincinnati, Ohio

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • University of Cincinnati Cancer Center-West Chester

    West Chester, Ohio

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • UT MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia Cancer Center

    Charlottesville, Virginia

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.